share_log

Moderna涨6%，研究人员将基于其mRNA平台进行艾滋病毒疫苗新试验

Moderna is up 6%, and researchers will conduct new HIV vaccine trials based on its mRNA platform.

智通財經APP ·  Apr 9, 2021 22:14

Friday, April 9Moderna (MRNA.US)Shares rose, rising more than 6% to $141.96 as of 2215 Beijing time.

It is reported that researchers will soon try to use the latest mRNA (messenger ribonucleic acid) technology platform to develop an HIV vaccine. Phase I clinical data show that the vaccine has shown the effectiveness of anti-HIV. By the end of this year, new trials of HIV vaccines will be conducted based on Moderna's mRNA platform.

Responsible editor: Guo Mingyu

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment